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Abstract
Background: We have previously described the existence of two phenotypically distinct cell subsets in ALK-positive
anaplastic large cell lymphoma (ALK + ALCL) based on their differential responsiveness to a Sox2 reporter (SRR2),
with reporter-responsive (RR) cells being more tumorigenic and chemoresistant than reporter-unresponsive (RU)
cells. However, the regulator(s) of RU/RR dichotomy are not identified. In this study, we aim to delineate the key
regulator(s) of RU/RR dichotomy.
Methods: JASPER motif match analysis was used to identify the putative factors binding to SRR2 sequence. SRR2
probe pull-down assay and quantitate real-time PCR were performed to analyze the regulation of Sox2 transcriptional
activity by MYC. Methylcellulose colony formation assay, chemoresistance to doxorubicin and mouse xenograft study
were performed to investigate the biological functions of MYC. PCR array and western blotting were executed to study
related signaling pathways that regulate MYC expression. Immunofluorescence and immunohistochemistry assay were
initiated to evaluate the expression of MYC and its correlation with its regulator by chi-square test analysis in human
primary tumor cells.
Results: We identified MYC as a potential regulator of RU/RR dichotomy. In support of its role, MYC was highly expressed
in RR cells compared to RU cells, and inhibition of MYC substantially decreased the Sox2/SRR2 binding, Sox2
transcriptional activity, chemoresistance, and methylcellulose colony formation. In contrast, enforced expression
of MYC in RU cells conferred the RR phenotype. The Wnt/β-catenin pathway, a positive regulator of MYC, was
highly active in RR but not RU cells. While inhibition of this pathway in RR cells substantially decreased MYC
expression and SRR2 reporter activity, experimental activation of this pathway led to the opposite effects in RU cells.
Collectively, our results support a model in which a positive feedback loop involving Wnt/β-catenin/MYC and Sox2
contributes to the RR phenotype. In a mouse xenograft model, RU cells stably transfected with MYC showed
upregulation of the Wnt/β-catenin/MYC/Sox2 axis and increased tumorigenecity. Correlating with these findings, there
was a significant correlation between the expression of active β-catenin and MYC in ALK + ALCL primary tumor cells.
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Conclusions: A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell
subset in ALK + ALCL.
Keywords: Intra-tumoral heterogeneity, MYC, Sox2, Wnt/β-catenin, Cancer stemness, ALK-positive anaplastic large cell
lymphoma
Background
ALK-positive anaplastic large cell lymphoma (ALK +
ALCL) is a specific type of non-Hodgkin lymphoma of
null/T cell lineage occurring most frequently in young
adults and children [1, 2]. Approximately 80% of ALK +
ALCL patients carry the chromosomal translocation,
t(2;5)(p23;q35), that leads to the generation of the abnor-
mal fusion protein NPM-ALK [1, 2]. By virtue of its
constitutively active tyrosine kinase activity, NPM-ALK
drives oncogenesis primarily by binding to and phos-
phorylating a host of signaling proteins, such as STAT3
and PI3K, thereby deregulating these signaling pathways
[1]. From the clinical perspective, ALK + ALCL tumors
are typically aggressive. Complete remission can be
induced in most pediatric ALK + ALCL patients with
conventional chemotherapy, while chemoresistance and
disease relapses occur in a substantial proportion of
adult patients [1]. The biological basis of chemoresis-
tance in ALK + ALCL patients is incompletely under-
stood, but a recent report [3] describing the existence of
cancer stem-like cells (CSCs) raises the possibility that
these cells may play a role, similar to how CSCs might
contribute to chemoresistance and cancer relapses in
other cancer models [4, 5].
Sox2, one of the four master transcriptional factors in-
volved in re-programming fibroblasts to inducible pluri-
potent stem cells, is normally expressed in embryonic
stem cells [6]. Recently, aberrant expression of Sox2 has
been found in a relatively large number of cancer types,
including breast cancer [7, 8], melanoma [9], and ALK +
ALCL [10]. Sox2 expression in these cancers has been
shown to correlate with cancer stemness properties,
such as chemoresistance [11], tumor initiation [8, 9],
and self-renewal [9]. Using a Sox2 reporter containing
the SRR2 (Sox2 Regulatory Region-2) sequence, we pre-
viously identified the existence of two phenotypically
distinct cell subpopulations in ALK + ALCL cell lines,
with a small subset of cells being Sox2active (currently
denoted as Reporter Responsive, RR) and the majority of
the cells being Sox2inactive (denoted as reporter unre-
sponsive, RU) [10]. Importantly, the sorted/purified RR
cells were found to be significantly more tumorigenic
and stem-like compared to their RU counterparts [10].
Sox2 is directly implicated, since siRNA knockdown of
Sox2 resulted in a dramatic abrogation of these features
[10]. As the expression level and subcellular localization
of Sox2 were found to be similar between RU and RR
cells, we concluded that the RU/RR dichotomy is not a
result of a differential Sox2 expression and localization
between these two cell subsets [10]. In view of the link
between the RR phenotype and CSC features in ALK +
ALCL, we believe that it is of paramount importance to
understand the biochemical basis of how the RU/RR
dichotomy is regulated.
We hypothesized that Sox2 is more transcriptionally
active in RR cells because Sox2 can bind to DNA more
efficiently in this cell subset. With this hypothesis, our
strategy involved bioinformatics analyses of the SRR2
sequence, in order to identify potential transcriptional
factor(s) that regulate the DNA binding of Sox2. With
these studies, we identified that a positive feedback loop
involving the Wnt/β-catenin/MYC/Sox2 axis defines a
highly tumorigenic and chemoresistant cell subset in
ALK + ALCL.
Methods
Primary tumors, cell lines, and treatments
All primary tumors were diagnosed at the Cross Cancer
Institute (Edmonton, Alberta, Canada), and the diagnos-
tic criteria were based on those described in the WHO
classification scheme. The use of these tissues has been
approved by our institutional ethics committee. All cell
lines were all grown and expanded in RPMI 1640 (Invi-
trogen, Life Technologies, Grand Island, NY) supple-
mented with 10% fetal bovine serum (FBS, Invitrogen),
1% penicillin streptomycin (Thermo Fisher Scientific
Canada), and 200 ng/mL puromycin dihydrochloride
(Sigma-Aldrich, St. Louis, MO) in 5% CO2 atmosphere
at 37 °C. Puromycin, G418, 10074-G5, quercetin, doxo-
rubicin, crizotinib, stattic, and iodonitrotetrazolium
chloride were all purchased from Sigma-Aldrich. All
treatments were performed following the manufacturer’s
instructions.
Cell sorting of RU and RR cells
All the RU and RR cells used in this study are sorted
and purified RU and RR cells (purity > 95%). Briefly, par-
ental SupM2 and Karpas 299 cells were stably trans-
fected with lentivirus-based SRR2 reporter which contains
two readouts including GFP intensity and luciferase activ-
ity, as well as puromycin antibiotic marker [10]. The
reporter stably transfected cells were subjected to flow
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cytometric instrument for cell sorting based on the GFP
intensity. The 10% of very GFP-negative cells were sorted
as RU cells, and the sorted GFP-positive cells were RR
cells. The sorted and purified RU and RR cells were subse-
quently cultured in cell culture medium with 200 ug/mL
puromycin.
Short interfering RNA and transfections
Short interfering RNAs (siRNAs) for MYC, β-catenin,
Sox2, and scrambled siRNA were purchased from
Dharmacon (Lafayette, CO). Transient transfections of
ALK + ALCL cells with siRNAs were performed using
the Electro square electroporator BTX ECM 800 (225 V,
8.5 ms, 3 pulses). Briefly, 400 pmol of siRNA were used
per 5 million ALK + ALCL cells. The efficiency of target
gene inhibition was assessed using western blots.
Luciferase assay
The luciferase assay kit was purchased from Promega
(Madison, WI), and luciferase activity was measured
following the manufacturer’s protocol.
Transwell assay
The 6-well plates of polyester transwell permeable
supports with 0.4-μm pore size were purchased from
Corning Inc (Toronto, Ontario, Canada). Briefly, 0.5
million of RU cells and RR cells were seeded in the
upper chamber and lower chamber, respectively, and
cultured for 72 h. Different ratios of RU/RR cells (RR
cells were diluted by RU cells) were also included in this
experiment. The same number of RU cells co-cultured
with RU cells in the lower chamber was included as con-
trol group. Then, the luciferase assay and western blot
studies were performed. Note that the upper chamber
and lower chamber were seeded with the same number
of cells in this experiment.
Western blots
Western blot studies were performed as described
previously.2
Antibodies reactive to phosphorylated MYCS62 (E1J4K),
MYC (D84C12), Sox2 (D6D9), β-catenin (D10A8), phos-
phorylated GSK3βS9 (D85E12), LEF1(C18A7), γ-tubulin
antibody (#5886), and histone deacetylase 1 (HDAC-1) anti-
body (#2062) were purchased from Cell Signaling Technol-
ogy (Danvers, MA); α-tubulin antibody (TU-02), β-catenin
(H-102), and β-actin antibody (sc-130300) were purchased
from Santa Cruz (Dallas, TX); antibody reactive to active
β-catenin (8E7) was purchased from Merck Millipore.
Immunohistochemistry and immunofluorescence studies
Anti-MYC (Y69) antibody (Abcam, Cambridge, MA)
was used (1:300 dilution) in the immunohistochemistry
assay, following the procedures described previously [12].
MYC (Y69) antibody (1:300 dilution) and anti-active β-ca-
tenin (8E7) antibody (Merck Millipore, Toronto, Ontario,
Canada) (1:200 dilution) were used in immunofluores-
cence double staining. The procedures for the
immunofluorescence assay were briefly described as
below. Formalin-fixed, paraffin-embedded tissue sections
were deparafinized and hydrated. Heat-induced epitope
retrieval was performed using citrate buffer (pH = 6) and a
pressure cooker using microwave. Tissue sections were
then permeabilized for 10 min with 0.2% Triton X-100 in
1× PBS containing 10 mM HEPES and 3% BSA (Sigma-
Aldrich), followed by the block with 1× PBS containing
10 mM HEPES and 3% BSA for 1 h. The tissue sections
were incubated with primary antibodies reactive to active
β-catenin and c-Myc which are diluted in 1× PBS with
10 mM HEPES and 1% BSA overnight in 4 °C. The next
day, after three times of washes with 1× PBS (30 min),
tissue sections were incubated with secondary antibodies
(Alexa Fluor 594 goat anti-rabbit antibody and Alexa
Fluor 488 goat anti-mouse antibody, Invitrogen, Burling-
ton, CA), diluted in 1× PBS, 1:300 for 1 h. After washing
in 1× PBS, tissues were incubated in 1 μg/mL Hoechst
33342 (Sigma-Aldrich, B2261) for 10 min, followed by
washes in 1× PBS and mounted with Mounting Medium
(Dako, Mississauga, Ontario, Canada). Cells were visual-
ized with a Zeiss LSM510 confocal microscope (Carl
Zeiss, Heidelberg, Germany) at the Core Cell Imaging
Facility, Cross Cancer Institute, University of Alberta,
Edmonton, Canada.
SRR2 probe binding assay
Cells were harvested and washed with cold PBS twice,
following by cytoplasmic and nuclear fractionation using
the Pierce NE-PER kit (Fisher Scientific Canada). Three
hundred micrograms of nuclear proteins was incubated
with or without 3 pmol of biotin-labeled SRR2 probe
(constructed by IDT, Edmonton, Alberta, Canada) for
0.5 h by rotating at room temperature. Streptavidin agar-
ose beads (75 μL, Fisher Scientific) were added to each
sample, following by overnight rotation at 4 °C. The next
day, the samples were washed with cold PBS three times
for 30 min in total, and protein was eluted at 100 °C in
4X protein loading buffer for 5 min, followed by western
blot study.
The sequence of the SRR2 probe: 5′-AAGAATTT
CCCGGGCTCGGGCAGCCATTGTGATGCATATAGG
ATTATTCACGTGGTAATG-3′
The underlined sequence is the Sox2 consensus sequence.
SCID mouse xenograft studies
Twelve CB-17 strain SCID male mice, purchased from
Taconic (Hudson, NY), were housed in a virus- and
antigen-free facility supported by the Health Sciences
Laboratory Animal Services at the University of Alberta
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and were cared for in accordance with the Canadian
Council on Animal Care guidelines. All experimental
protocols involving mice were reviewed and approved by
the University of Alberta Health Sciences Animal
Welfare Committee. Briefly, 2 million cells of SupM2-
RU-EV, SupM2-RU-MYC, and SupM2-RR-EV growing
exponentially were injected into both flanks of 4-week-old
mice, four mice each group. The tumor sizes were mea-
sured twice every week. These animals were sacrificed
when a tumor reached 10 mm in the greatest dimension.
Statistical analysis
Data is expressed as mean ± standard deviation. The
statistical analysis was performed using GraphPad Prism
5 (La Jolla, CA), and the significance of two independent
groups of samples was determined using Student’s t test.
Statistical significance is denoted by * (P < 0.05) and **
(P < 0.01). For additional methods, see Additional file 1.
Results
The identification of MYC as a key regulator of the RU/RR
dichotomy
To decipher the factor(s) that regulate the RU/RR
dichotomy, we examined SSR2 using the JASPAR motif
matches analysis. As summarized in Fig. 1a, we identi-
fied a number of transcriptional factors that show a high
probability of binding to SRR2. Among these candidates,
MYC was found to be the highest expressed factor in
RU/RR cell subsets derived from SupM2 and Karpas 299
cells (Fig. 1b). Accordingly, RR cells derived from both
cell lines expressed a significantly higher level of MYC
mRNA compared to their RU counterparts (Fig. 1b).
This finding correlates well with that of western blot
study (Fig. 1c). In the same western blot study, we also
found that RR cells expressed a higher level of phos-
phorylated MYCS62 (i.e., p-MYCS62), the active form of





Fig. 1 RR cells express a substantially higher level of MYC than RU cells. a The top 11 factors that are predicated to bind to SRR2 sequence by
JASPAR motif matches analysis at P < 0.001. b The relative mRNA expression levels of putative SRR2 binding factors assessed by quantitative
RT-PCR (qRT-PCR). GAPDH was used as internal control, and all the mRNA expression levels were normalized to that of Sox2 in RU cells. Note that
the mRNA levels of POU5F1 and SOX17 in both cell lines were undetectable by qRT-PCR. c The protein levels of p-MYCS62 and MYC in RU and RR
cells derived from SupM2 and Karpas 299. d The subcellular localization of p-MYCS62 and MYC in RU and RR cells derived from SupM2 and Karpas
299, assessed by the nuclear cytoplasmic fractionation assay
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cytoplasmic fractionation, we found that most of the
MYC protein expressed in both RU and RR cells was
predominantly localized in the nuclei (Fig. 1d).
To evaluate the relevance of MYC in the context of
SRR2 reporter responsiveness, we knocked down MYC
expression using siRNA and found that SRR2 luciferase
activity was significantly reduced by ~40–60% in RR
cells derived from SupM2 and Karpas 299 cells (Fig. 2a).
Similar results were obtained when MYC was inhib-
ited by using 10074-G5, a pharmacological agent
known to inhibit MYC-Max heterodimerization and
their DNA binding [13], or MYC-Mad transfection to
antagonize the MYC-Max transcriptional activity
(Fig. 2b and Additional file 2: Figure S1) [14]. As a
comparison, siRNA knockdown of Sox2 resulted in a
similar reduction in SRR2 luciferase activity (Add-
itional file 3: Figure S2a). Correlating with these find-
ings, transfection of MYC into RU derived from the
two cell lines resulted in a significant increase in
SRR2 luciferase activity, even though the level remained
to be substantially lower than that of RR cells






Fig. 2 The high MYC expression contributes to the RR phenotype. a The SRR2 luciferase activity in RR cells derived from SupM2 and Karpas 299
cells with scr siRNA or MYC siRNA transfection. The western blots below showed the knockdown efficiency of MYC. b The SRR2 luciferase activity
in RR cells with the treatment of 10 μM 10074-G5 for 24 h. Cells with DMSO treatment were used as a negative control. c RU and RR cells derived
from both cell lines were transiently transfected with pcDNA3.3-MYC (i.e., MYC). pcDNA empty vector (EV) was included as a negative control. The
western blots showed the MYC transfection efficiency. Below shows the SRR2 luciferase activity in RU and RR cells with either EV or MYC transient
transfection. d The clonogenicity of RR cells in the presence of 5 μM 10074-G5 by using the methylcellulose colony formation assay. Cells with
DMSO treatment were included as a control. The relative colony numbers analyzed in triplicate were shown in the lower panel. The colony will be
counted if only its size is equal or larger than the one that was pointed by the bolded arrow. One representative result was shown here. e The cell
growth inhibition in RR cells originated from SupM2 and Karpas 299 induced by the treatment of doxorubicin (20 and 50 ng/mL, respectively), or
10074-G5 (5 μM), or combination of the doxorubicin and 10074-G5 for 48 h, assessed by the MTS assay. f The cell growth inhibition induced by
varying doses of doxorubicin for 48 h in RU cells derived from SupM2 with either EV or MYC transient transfection, assessed by the MTS assay. g
The clonogenicity of RU and RR cells from SupM2 with either EV or MYC transient transfection, assessed by the methylcellulose colony formation
assay. The relative colony numbers analyzed in triplicate were shown in the lower panel. The colony will be counted if only its size is equal or
larger than the one that was pointed by the bolded arrow. One representative result was shown here
Wu et al. Journal of Hematology & Oncology  (2016) 9:120 Page 5 of 14
cells from both cell lines also led to a significantly in-
creased SRR2 reporter activity (Fig. 2c). Taken together,
these findings suggest that MYC is a key regulator of the
SRR2 reporter activity.
We then asked if inhibition of MYC in RR cells also
decrease the clonogenicity and chemoresistance that are
associated with the RR phenotype. As shown in Fig. 2d,
e and Additional file 4: Figure 3Sa–c, pharmacologic in-
hibition of MYC using 10074-G5 in RR cells resulted in
a significant decrease in methylcellulose colony formation
and sensitization of these cells to doxorubicin-induced cell
growth inhibition. Regarding the sensitization to doxo-
rubicin by the MYC inhibitor, we also performed cell cycle
analysis, which showed that apoptosis induced by
doxorubicin was potentiated by 10074-G5, as evidenced
by the significant increases in the Sub-G0/1 phase
(Additional file 4: Figure S3c, d). The occurrence of apop-
tosis in this experiment was further confirmed by our PI
staining results (Additional file 4: Figure S3e) as well as
our morphologic examination (not shown). Accordingly,
compared to RR cells, RU cells were significantly less sen-
sitive to cell growth inhibition induced by 10074-G5
(Additional file 4: Figure S3e). Furthermore, compared to
cells transfected with empty vector, RU cells originated
from SupM2 with MYC transfection exhibited signifi-
cantly increased doxorubicin resistance and clonogenicity
in methylcellulose soft agar (Fig. 2f, g). Again, a signifi-
cantly increased clonogenicity was also observed in RR






Fig. 3 MYC promotes the SRR2 probe binding and the transcriptional activity of Sox2. a SRR2 probe pull-down assay was performed in RU and
RR cells originated from Karpas 299 cells to compare the bindings between Sox2, MYC, and SRR2 probes. The western blots in the right panel
showed the input of the pull-down assay. b The SRR2 probe pull-down assay was performed to assess the Sox2, MYC, and SRR2 binding in RU
cells with MYC transient transfection, as compared to cells with EV transfection. The western blots in the right panel showed the input of the pull--
down assay. c The relative mRNA levels of Sox2 downstream target genes such as WNT2B, CTNNB1, and BCL9 in RU cells originated from SupM2
with EV or MYC transient transfection at 48 h. d RR cells derived from SupM2 were subjected with 10 μM MYC inhibitor 10074-G5 for 0, 4, 6, 8,
and 24 h, and then the SRR2 probe pull-down assay was performed. The western blots in the right panel showed the input. e RR cells originated
from both cell lines were subjected with 10 μM 10074-G5 for 8 h, then qRT-PCR assay was performed to assess the mRNA levels of MYC, CTNNB1,
and BCL9. f The SRR2 luciferase activity in RU and RR cells originated from SupM2 with EV or pcDNA-SOX2-FLAG (i.e., SOX2-FLAG) transfection at
48 h. The western blots showed the transfection efficiency of SOX2-FLAG. g The Sox2-SRR2 binding ability in RU and RR cells originated from
SupM2 with EV or SOX2-FLAG transfection at 48 h
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MYC promotes Sox2-SRR2 binding and the transcriptional
activity of Sox2
The observation that both RU and RR cell subsets
express a similar level of Sox2 protein raised the possi-
bility that MYC upregulates SRR2 activity by increasing
Sox2-SRR2 binding and Sox2 transcriptional activity. In
support of this concept, when we performed pull-down
assay using a biotin-labeled SRR2 probe, we found abun-
dant MYC-SRR2 binding in RR cells but not RU cells
(Fig. 3a and Additional file 5: Figure S4a); a similar pat-
tern of the Sox2-SRR2 interaction was also found in RU
and RR cells (Fig. 3a and Additional file 5: Figure S4a).
Furthermore, enforced expression of MYC in RU cells
led to substantially more Sox2 pulled down by the SRR2
probe, while the total Sox2 protein level was only slightly
increased in this experiment (Fig. 3b). Correlating with
this increased Sox2-SRR2 binding, the mRNA levels of
several genes including WNT2B, CTNNB1, and BCL9
were significantly increased (Fig. 3c), all of which were
shown to be Sox2 downstream targets in RR cells (see
“The positive regulatory loop involving Sox2, Wnt/β-ca-
tenin, and MYC in RR cells” section). Additionally,
10074-G5 treatment of RR cells from SupM2 cells
resulted in a rapid and dramatic decrease in Sox2-SRR2
binding (Fig. 3d), with the total protein levels of MYC
and Sox2 being unaffected in this timeframe (i.e., 4 h).
Similar results were also observed when we knocked
down MYC using siRNA (Additional file 5: Figure S4b).
As shown in Additional file 5: Figure S4c, we also per-
formed chromatin immunoprecipitation-qPCR, and we
found a significant decrease in Sox2-SRR2 binding upon
10074-G5 treatment. Correlating with this decreased
Sox2-SRR2 binding, the mRNA levels of two Sox2
downstream targets including CTNNB1 and BCL9 were
also markedly downregulated in RR cells upon MYC in-
hibition by using 10074-G5 at 8 h, with the Sox2 protein
level not appreciably altered in this time point (Fig. 3e).
We found evidence that Sox2 alone is not sufficient to
regulate Sox2-SRR2 binding and the SRR2 activity in RU
cells. As shown in the left panel of Fig. 3f, we transfected
SOX2-FLAG in these two cell subsets derived from
SupM2, and it is evident that Sox2 overexpression did
not significantly increase SRR2 luciferase activity in RU
cells; in contrast, the same experimental manipulation
led to a significant increase in the reporter activity in RR
cells. Accordingly, Sox2-flag overexpression did not
appreciably increase Sox2-SRR2 binding in RU cells, but
a substantial increase of Sox2-SRR2 binding was
observed in RR cells (Fig. 3g).
The high level of MYC in RR cells is attributed to the Wnt/
β-catenin pathway
To explain why MYC is preferentially expressed at a
high level in RR cells, we first evaluated the activation
status of NPM-ALK/STAT3 axis between these two cell
subsets. Consistent with our previous studies [10], the
expression and activation levels of NPM-ALK and STAT3
were similar between RU and RR cells (Additional file 6:
Figure S5a). Pharmacologic inhibition of NPM-ALK (crizo-
tinib) or STAT3 (stattic) dramatically decreased the expres-
sion of both Sox2 and MYC in RU and RR cells equally
well, and these findings correlated with a reduction of the
SRR2 luciferase activity by ~50–70% in both cell subsets
(Additional file 6: Figure S5b, c). Based on these findings, it
is evident that, while the NPM-ALK/STAT3 axis contrib-
utes to a basal expression level of MYC, it does not explain
the differential MYC expression between RU and RR cells.
We then asked if the Wnt/β-catenin pathway is a con-
tributing factor, as this pathway is known to upregulate
MYC in other cancer cell types [15–17]. Firstly, we per-
formed Wnt signaling pathway PCR array to compare
RU and RR cells derived from SupM2. Compared to RU
cells, RR cells expressed higher levels (>1.4-fold) of gene
expression in 24 of the 87 targets included in the array
(Additional file 7: Figure S6). We then employed quantita-
tive RT-PCR and confirmed 5 of the 24 targets being signifi-
cantly different between RU and RR cells. Other than MYC,
4 targets (WNT2B, CTNNB1, LEF1, and BCL9) are known
to be directly related to the Wnt/β-catenin pathway (Fig. 4a).
Western blot studies showed that RR cells expressed a
substantially higher level of the active form of β-catenin
(non-phosphorylated β-catenin), total β-catenin, phos-
phorylated GSK3βS9 (i.e., pGSK3βS9) and LEF1 (Fig. 4b),
strongly suggesting that the Wnt/β-catenin pathway is
indeed highly activated in RR cells but not RU cells.
To prove that the Wnt/β-catenin pathway contributes to
the differential MYC expression and SRR2 activity between
RU and RR cells, we knocked down β-catenin using
siRNA, and found that siRNA knockdown of β-catenin in
RR cells led to a dramatic decrease in the MYC expression
level and SRR2 luciferase activity (Fig. 4c). Similar results
were obtained when RR cells were subjected with quer-
cetin, a β-catenin pharmacologic inhibitor (Fig. 4d) [18].
Importantly, enforced expression of MYC in RR cells abro-
gated the inhibitory effects of quercetin on SRR2 luciferase
activity (Additional file 8: Figure S7).
Since RR cells expressed more ligands for the Wnt/β-
catenin pathway (such as Wnt2B) than RU cells, we
asked if soluble factors produced by RR cells can in-
crease MYC expression and SRR2 activity in RU cells.
To test this, we used the transwell co-culture system
that is illustrated in Fig. 4e. As shown in Fig. 4f, we
found that the SRR2 luciferase activity in RU cells was
significantly increased after 72 h of co-culture with RR
cells (RR/RU ratio = 1:1). By western blot studies
(Fig. 4g), we confirmed that the Wnt/β-catenin pathway
in RU cells was upregulated after 72 h of co-culture with
RR cells, as evidenced by the increased protein expressions
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of active β-catenin, β-catenin, and LEF1. Accordingly, MYC
was also upregulated. This conversion of RU cells into RR
cells is dependent on the RR/RU ratio, as we did not
observe appreciable conversion when the RR/RU ratio was
decreased to below 1:5 (Additional file 9: Figure S8).
To further support that the Wnt/β-catenin pathway
can upregulate MYC and SRR2 activity in RU cells, we
transfected RU cells derived from Karpas 299 with con-
stitutively active CTNNB1 (i.e., CA-CTNNB1) and found
that the expression of MYC and SRR2 luciferase activity
increased, coupled with the significantly increased clono-
genicity (Additional file 10: Figure S9a–c).
The positive regulatory loop involving Sox2, Wnt/β-
catenin, and MYC in RR cells
In view of several recent publications reporting that
Sox2 can activate the Wnt/β-catenin pathway in a
number of cell types [11, 19, 20], we asked if Sox2 also
can exert similar effects in ALK + ALCL. As shown in
Fig. 5a, siRNA knockdown of Sox2 in RR cells signifi-
cantly decreased the transcript levels of SOX2, WNT2B,
CTNNB1, MYC, and BCL9. Furthermore, the protein
levels of p-MYCS62 and MYC were dramatically
decreased in RR cells upon Sox2 siRNA knockdown
(Fig. 5b). Correlating with the fact that Sox2 is relatively
transcriptionally quiescent in RU cells, the expressions
of p-MYCS62 and MYC in these cells did not change
appreciably in response to Sox2 knockdown (Fig. 5b).
Taken together, these findings support the existence of a
positive feedback loop involving Wnt/β-catenin, MYC,
and Sox2 in RR cells. In other words, in RR cells, the
high level of MYC promotes the transcriptional activity
of Sox2, which in turn activates the Wnt/β-catenin path-






Fig. 4 The Wnt/β-catenin pathway contributes to the high MYC expression in RR cells. a The relative mRNA levels of WNT2B, CTNNB1, LEF1, MYC,
and BCL9 in RU and RR cells derived from SupM2 and Karpas 299, assessed by qRT-PCR. b The protein levels of active β-catenin, β-catenin,
pGSK3βS9, GSK3β, LEF1, and Sox2 in RU and RR cells. c The SRR2 luciferase activity in RR cells with scr siRNA or β-catenin siRNA transfection at
48 h. The western blots below showed the knockdown efficiency of β-catenin and MYC. d The SRR2 luciferase activity in RR cells treated with
DMSO or 50 μM quercetin, a pharmacological β-catenin inhibitor for 24 h. The western blots below showed the knockdown efficiency of β-catenin
and MYC. e The diagram showed the design of transwell co-culture experiment. f The SRR2 luciferase activity in RU cells in the control group and the
experimental group (Exp-group). g The western blots showed the protein levels of β-catenin, LEF1, and MYC in RU cells derived from SupM2 in the
control group and experimental group
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contrast, in RU cells, Sox2 does not effectively activate
the Wnt/β-catenin pathway due to the relatively low
level of MYC; in the absence of active Wnt/β-catenin
pathway, MYC remains to be lowly expressed. A model
summarizing this concept is illustrated in Fig. 5c.
MYC is heterogeneously expressed in primary tumor
samples, and it co-localizes with active β-catenin
Our results suggest that high levels of Wnt/β-catenin
activation and MYC expression are the defining features
of the RR phenotype. With this model, we examined the
expression of MYC and active β-catenin (as a surrogate
marker of Wnt activation) using double immunofluores-
cence staining analyzed by using confocal microscopy.
After evaluating tumor cells (10 random fields) derived
from 3 cases, we found a highly significant correlation
between the expression of MYC and active β-catenin
(P < 0.0001) (Fig. 6a and the table below, 400×). We
also performed immunohistochemistry to study MYC
expression in 7 additional cases of formalin-fixed/par-
affin-embedded ALK + ALCL tumors. As illustrated in
Fig. 6b, MYC is heterogeneously expressed in tumor
cells and two representative fields from a case were
shown here (400×). MYC expression was restricted to
a small subset (~30%) of neoplastic cells; benign
lymphocytes and fibroblasts were negative.
RU cells stably transfected with MYC are biochemically
and phenotypically similar to RR cells
Finally, to fully assess the biological roles of MYC in
ALK + ALCL, we generated RU cell clones derived from
SupM2 that were stably transfected with MYC (i.e.,
SupM2-RU-MYC). Compared to the negative control
cells, SupM2-RU-MYC cells showed activation of the
Wnt/β-catenin pathway, as evidenced by their elevated
expression levels of active β-catenin, total β-catenin,
pGSK3βS9, GSK3β, and LEF1 (Fig. 7a). SupM2-RU-MYC
cells also expressed higher mRNA levels of MYC,
WNT2B, CTNNB1, and BCL9 that were comparable to
those of SupM2-RR cells stably transfected with an
empty vector (i.e., SupM2-RR-EV) (Fig. 7b). We then
performed mouse xenograft studies comparing the
tumorigenecity of SupM2-RU-MYC cells with SupM2-
RU-EV cells or SupM2-RR-EV cells. As shown in Fig. 7c,
d, SupM2-RU-MYC cells displayed a significantly higher
a
b c
Fig. 5 The positive regulatory loop of Sox2–Wnt/β-catenin–MYC in RR cells. a qRT-PCR assay was performed to analyze the relative mRNA levels
of WNT2B, CTNNB1, MYC, and BCL9 in RR cells derived from SupM2 and Karpas 299 cells with scr siRNA or Sox2 siRNA transfection at 48 h. b The
protein levels of Sox2, p-MYCS62, and MYC in RR cells with scr siRNA or Sox2 siRNA transfection at 48 h. c The cell models of RR and RU cells
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tumorigenicity compared to SupM2-RU-EV cells and ex-
hibited comparable tumorigenicity to that of SupM2-
RR-EV cells.
Discussion
One of the key findings of this study is that MYC
appears to be the key regulator of the RU/RR dichotomy
in ALK + ALCL. Our study showed that MYC is crucial
for the SRR2 activity and the RR phenotype, since
knockdown of MYC by siRNA or pharmacological agent
in RR cells abolishes the SRR2 activity and the RR
phenotype. Importantly, we found evidence that the
regulatory function of MYC is related to its ability to
influence the DNA binding and transcriptional activity
of Sox2. This model explains why RU and RR cells have
dramatically different SRR2 activity despite their
approximately equal Sox2 protein expression level and
nuclear localization. As illustrated in Fig. 5c, a relatively
high level of MYC, perhaps exceeding a specific thresh-
old, permits the binding of Sox2 to SRR2 and its execu-
tion as a transcriptional factor. To our knowledge, this is
the first report describing this novel relationship
between MYC and Sox2 in cancer cells. Exactly how a
high level of MYC promotes the DNA binding of
Sox2 is unknown. A recently published observation
[21] that the target genes of MYC substantially over-
lap with those of Sox2 suggests that MYC or the
MYC protein complex may physically direct Sox2 to
the gene promoters, and facilitate its DNA binding.
This concept is supported by a previously published
data that MYC and Sox2 were found co-localized in a
protein complex [22]. Furthermore, MYC has been
a b
Fig. 6 MYC is heterogeneously expressed and its expression is co-localized with active β-catenin in ALK + ALCL tumor cells. a Immunofluorescence
assay was performed in 3 cases of primary tumors with MYC and active β-catenin double staining, and the results showed MYC is significantly
(P < 0.0001) co-localized with active β-catenin in tumor cells (shown in the table). Ten random fields of the 3 cases were chosen under microscope,
and one representative field (400×) was shown here. The correlation analysis was performed by Fisher’s exact test. b Two different fields of a case of
ALK + ALCL primary tumor immunostained for MYC were shown. The above showed a focus with many lymphoma cells strongly positive for MYC
(red arrows). A lymphoma cell that was only dimly positive for MYC was also noted (black arrow). Scattered reactive small lymphocytes and benign
fibroblasts in the background were negative. Below showed another focus in which lymphoma cells strongly positive for MYC being not as frequent. A
good number of lymphoma cells negative or weakly positive for MYC were noted (black arrow, immunohistochemistry, 400×)
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recently reported to regulate gene expression as a
general transcriptional amplifier [23, 24].
MYC, one of the four inducible pluripotent stem cell
factors [25], is known to contribute to cancer stemness
in cancer cells, including the tumor-initiating ability
[26, 27], chemoresistance [28, 29], and self-renewal
[30]. Moreover, the expression level of MYC was
found to be relatively high in CSCs derived from sev-
eral cancer types when compared to bulk cell popula-
tions [30–34]. A recent study has highlighted that the
CSCs from glioma are more sensitive than the bulk
tumor cells to cell death induced by MYC inhibition
[30]. This observation correlates well with our finding
that RR cells derived from ALK + ALCL are more
sensitive to cell growth inhibition induced by MYC
inhibition, as compared to RU cells. How exactly
MYC mediates these biological effects is not completely
understood, but it is believed that MYC can regulate as
many as ~15% of human genes that are involved in critical
cellular processes including chromatin remodeling, cell
cycle control, metabolism, and self-renewal [27, 35].
Importantly, MYC is found to bind to and regulate SOX2
gene expression in CSCs derived from triple negative
breast cancer, suggesting MYC can regulate cancer stem-
ness by modulating the expression of other critical embry-
onic stem cell markers such as Sox2 [36]. With this
context, we believe that findings of this study have
advanced by our understanding of how MYC may pro-
mote stem-like features, namely by enhancing Sox2/DNA
binding and Sox2 transcriptional activity.
The role of MYC in ALK + ALCL has not been exten-
sively studied, and we are aware of only two publications
that directly studied MYC in these tumors. In a recent
study, shRNA knockdown of MYC was found to reduce
the growth of ALK + ALCL cells in vitro, although the




Fig. 7 RU cells stably transfected with MYC are biochemically and phenotypically similar with RR cells. a The protein levels of p-MYCS62, MYC,
active β-catenin, β-catenin, pGSK3βS9, GSK3β, LEF1, and Sox2 in the stably transfected cell lines SupM2-RU-EV, SupM2-RU-MYC, and SupM2-RR-EV.
b The relative mRNA levels of MYC, WNT2B, CTNNB1, and BCL9 in the three stable cell lines. c The diagram showed the design of mice xenograft
study. d The tumor growth rates of the three stable cell lines in the mouse xenograft study. The right panel showed the representative tumors
from the three groups at the termination point
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Consistent with this observation, we also found that
pharmacologic inhibition of MYC can significantly in-
hibit the growth in ALK + ALCL cells. Importantly, we
found that RR cells were found to be more sensitive to
MYC inhibition than RU cells, consistent with our
model that MYC carries more biological importance in
RR cells. The second study published described that
MYC in ALK + ALCL can be upregulated by NPM-ALK
[38], but the biological significance of this observation
was not assessed. Correlating with this finding, we also
found that NPM-ALK upregulates MYC. However, while
the NPM-ALK/STAT3 axis contributes to the expression
of MYC in both RU and RR cells, this pathway is not
responsible for the differential MYC expression between
these two cell subsets.
As the NPM-ALK/STAT3 signaling pathway is not the
key contributing factor to the differential expression of
MYC, we turned to the Wnt/β-catenin pathway, which
has been well documented to upregulate MYC in a var-
iety of human cancers [15–17]. Constitutive activation
of the Wnt/β-catenin pathway can be found in CSCs de-
rived from various cancer types [39–42]. Inhibition of
the Wnt/β-catenin pathway has been shown to decrease
stemness and tumorigenic potential in cancer cells [39–
42], and there is evidence that MYC is a mediator of the
stemness properties conferred by this pathway [43, 44].
A recent study suggested that MYC is the ultimate
downstream of β-catenin pathway-mediated enhanced
amplification and tumorigenesis of basal stem cells [44].
Our model is in line with these observations, although
our model highlights the importance of intra-tumoral
heterogeneity and suggests that a high activation level of
the Wnt/β-catenin pathway is a characteristic of RR
cells. While this concept has been brought up in a previ-
ous publication [41], our data has provided the mechan-
istic explanation as to how the Wnt/β-catenin pathway
may promote stemness for the first time. Specifically, a
high level of Wnt/β-catenin activity promotes a relatively
high level of MYC expression, which permits Sox2 to
exert its transcriptional activity. Furthermore, based on
our observations that Sox2 upregulates a number of
Wnt/β-catenin pathway ligands as well as β-catenin, we
have demonstrated, for the first time, a positive feedback
loop involving Wnt/β-catenin, MYC, and Sox2, and our
hypothetical model has been illustrated in Fig. 5c. Our
data supports a model in which this positive feedback
loop is the defining feature of RR cells in ALK + ALCL.
Here, we need to stress that our observation that block-
ing either NPM-ALK/STAT3 or Wnt/β-catenin nearly
diminished the expression of MYC in RR cells seems
against our hypothetical model. While we are aware that
the published literature [45, 46] demonstrating the recip-
rocal regulation between NPM-ALK/STAT3 and Wnt/β-
catenin in ALK +ALCL can help explain our observation.
In other words, suppression of one would attenuate the
activity of the other one.
Results from our immunofluorescence staining/con-
focal microscopy have provided further evidence to sup-
port the existence of the positive feedback loop
involving Wnt/β-catenin and MYC in a small cell subset
of ALK + ALCL. Thus, MYC significantly co-localizes
with active β-catenin in a very small number of tumor
cells. Regarding our immunohistochemical studies, we
would like to point out that, while we found only ~30%
of tumor cells being labeled with MYC, two previous
publications showed that MYC immunohistochemical
reactivity is detectable in the majority of tumor cells in
ALK + ALCL [37, 38]. This discrepancy may be due to
the use of different MYC antibodies and/or immuno-
staining protocols. In our experience, a substantially
higher number of MYC-positive cells can be obtained if
higher concentration of anti-MYC antibody is used. The
concentration of anti-MYC antibody we chose was based
on the observation that this antibody concentration is
optimal in revealing the intra-tumoral heterogeneity of
MYC expression.
Conclusions
In this study, we report that MYC is the key regulator of
the RU/RR dichotomy in ALK + ALCL. High level of
MYC promotes the DNA binding ability and transcrip-
tional activity of Sox2. Our studies have highlighted the
importance of the Wnt/β-catenin pathway in contribut-
ing to the high MYC expression in RR cells. The exist-
ence of a positive feedback loop involving the Wnt/
β-catenin/MYC/Sox2 axis defines a small cell subset in
ALK + ALCL that are characterized by high tumorigene-
city and chemoresistance.
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Additional file 1: Supplemental methods. (DOCX 127 kb)
Additional file 2: Figure S1. Knockdown of Sox2 by siRNA significantly
downregulated the SRR2 reporter activity in RR cells. The SRR2 luciferase
activity in RR cells derived from SupM2 and Karpas 299 with scrambled
siRNA (scr siRNA) or Sox2 siRNA transfection at 48 h. The western blots
showed the knockdown efficiency of Sox2 protein. (PDF 169 kb)
Additional file 3: Figure S2. Inhibition of MYC by MYC-MAD
transfection in RR cells significantly decreased the SRR2 luciferase activity.
The SRR2 luciferase activity in RR cells derived from SupM2 and Karpas
299 with EV or MYC-MAD transfection at 48 h. The western blots results
showed the protein levels of p-MYCS62 and MYC in RR cells from the two
cell lines after MYC-MAD transfection at 48 h; cells with EV transfection
were included as a control. (PDF 148 kb)
Additional file 4: Figure S3. Inhibition of MYC sensitizes cells to
doxorubicin in RR cells. (a) The left panel showed that RR cells originated
from SupM2 and Karpas 299 were treated with varying dosages of MYC
inhibitor 10074-G5 for 48 h, and then the cell growth was assessed by
the MTS assay. The dosage of 5 μM 10074-G5 was chosen for the following
drug combination study. The right panel showed that RR cells were treated
with varying dosages of doxorubicin for 48 h, and then the cell growth was
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assessed by the MTS assay. Fifty and 20 ng/mL doxorubicin were chosen in
RR derived from Karpas 299 and SupM2, respectively, for the following drug
combination study. (b, c) The cell cycle analysis was performed to assess the
Sub G0/1 fraction in RR cells derived from SupM2 induced by 20 ng/mL
doxorubicin, 5 μM 10074-G5, or combination of doxorubicin and 10074-G5
for 48 h; Cells with DMSO treatment were included as a control. (d) The PI
staining assay was also performed in the experiment described above. (e)
RU and RR cells were treated with varying doses of 10074-G5 for 72 h, then
followed by the MTS assay to assess the cell growth. (PDF 341 kb)
Additional file 5: Figure S4. Inhibition of MYC by 10074-G5 downregulates
the Sox2 downstream target genes in RR cells. (a) SRR2 probe pull-down assay
was performed in RU and RR cells originated from SupM2 cells to compare the
bindings between Sox2, MYC, and SRR2 probes. The western blots in the right
panel showed the input of the pull-down assay. (b) SRR2 probe pull-down
assay was performed in RR cells from SupM2 upon MYC siRNA transfection at
0, 8, 12, 24, and 48 h; the western blots in the right panel showed the input of
the pull-down assay. (c) Chromatin immunoprecipitation-qPCR assay was
employed to analyze the Sox2-SRR2 probe binding in RR cells derived from
SupM2 after 10 μM 10074-G5 treatment for 4 h. (PDF 204 kb)
Additional file 6: Figure S5. NPM-ALK/STAT3 is not differentially activated
or expressed between RU and RR cells. (a) The protein levels of pALKY1601, ALK,
pSTAT3Y705, and STAT3 in RU and RR cells derived from SupM2 and Karpas
299. (b, c) RR and RU cells were treated with either DMSO, or 100 nM ALK
inhibitor crizotinib, or 10 nM STAT3 inhibitor stattic for 24 h. The western blots
were employed to assess the expression/activation levels of NPM-ALK, STAT3,
MYC, and Sox2 in both RU and RR cells. The SRR2 luciferase activity in RU and
RR cells was also evaluated by the luciferase assay. (PDF.488KB) (PDF 458 kb)
Additional file 7: Figure S6. The Wnt/β-catenin pathway is more active
in RR cells than RU cells derived from SupM2. The Wnt pathway-specific
oligonucleotide PCR array was performed in RU and RR cells derived from
SupM2 cells. The data suggested that 24 out of 87 genes related with the
Wnt pathway were more highly expressed in mRNA level (>1.4-fold) in
RR cells than in RU cells. Note that one time experiment was performed
in this study. (PDF 102 kb)
Additional file 8: Figure S7. Overexpression of MYC significantly
attenuates the decreased SRR2 luciferase activity induced by inhibition of
β-catenin by using quercetin. The SRR2 luciferase activity in RR cells
derived from Karpas 299 with EV or MYC transfection in the presence of
50 μM quercetin for 24 h; cells with DMSO treatment were included as a
negative control. The SRR2 luciferase activity decreased by ~50% in RR
cells from Karpas 299 with EV transfection upon quercetin treatment,
whereas it only decreased by ~25% in cells with MYC transfection. The
MYC transfection efficiency was validated in Figure S2c. (PDF 36 kb)
Additional file 9: Figure S8. RU cells co-cultured with diluted (10:1) RR
cells or parental SupM2 cells did not show significantly increased SRR2
luciferase activity or upregulated MYC expression. SupM2-RU cells (50,000
cells in total seeded in the upper chamber) and various ratios (RU/RR =
1:1, 2:1, 5:1, 10:1) of SupM2-RR cells (seeded in the lower chamber) were
co-cultured in 6-well transwell plate for 72 h. SupM2-RU cells co-cultured
with the same number of SupM2-RU cells or parental SupM2 cells were
included in this experiment. MYC protein expression was also assessed in
this experiment. The results suggested that RU cells co-cultured with the
same number of RR cells showed significantly increased SRR2 luciferase
activity and a robust increased MYC expression, as compared to negative
control. In contrast, RU cells co-cultured with diluted RR cells (e.g., 10:1,
containing 5000 of RR cells and 45,000 of RU cells) or parental SupM2
cells did not exhibit significantly increased SRR2 luciferase activity and
only showed slight increase of MYC protein expression, as compared to
negative control. (PDF 164 kb)
Additional file 10: Figure S9. RU cells transfected with the
constitutively active CTNNB1 (CA-CTNNB1) acquire the RR phenotype.
(a) The protein levels of β-catenin and MYC in RU cells derived from
Karpas 299 with EV or CA-CTNNB1 transfection at 48 h. (b) The SRR2
luciferase activity in RU cells derived from Karpas 299 with EV or
CA-CTNNB1 transfection at 48 h. (c) The clonogenicity of RU cells
derived from Karpas 299 with EV or CA-CTNNB1 transfection, assessed
by the methylcellulose colony formation assay. The relative colony
numbers analyzed in triplicate were shown in the right panel. The
colony will be counted if only its size is equal or larger than the one
that was pointed by the bolded arrow. One of the representative
results were shown in the left panel. (PDF 154 kb)
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